Alvotech, Teva Secure US License Date For AVT04, A Proposed Biosimilar To Stelara; Reach Settlement And License Agreement With Johnson & Johnson Concerning AVT04
Portfolio Pulse from Benzinga Newsdesk
Alvotech and Teva have secured a US license date for AVT04, a proposed biosimilar to Stelara, and reached a settlement and license agreement with Johnson & Johnson concerning AVT04.
June 12, 2023 | 11:04 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Alvotech secures US license date for AVT04, a proposed biosimilar to Stelara, and reaches a settlement with Johnson & Johnson.
Alvotech's securing of the US license date for AVT04 and the settlement with Johnson & Johnson is a positive development for the company, as it allows them to move forward with the commercialization of the biosimilar. This could lead to increased revenues and growth for Alvotech.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Teva secures US license date for AVT04, a proposed biosimilar to Stelara, and reaches a settlement with Johnson & Johnson.
Teva's securing of the US license date for AVT04 and the settlement with Johnson & Johnson is a positive development for the company, as it allows them to move forward with the commercialization of the biosimilar. This could lead to increased revenues and growth for Teva.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
NEGATIVE IMPACT
Johnson & Johnson reaches a settlement and license agreement with Alvotech and Teva concerning AVT04, a proposed biosimilar to Stelara.
The settlement and license agreement with Alvotech and Teva concerning AVT04 could have a negative impact on Johnson & Johnson, as it may lead to increased competition for their product Stelara. This could result in a potential loss of market share and revenues for Johnson & Johnson.
CONFIDENCE 85
IMPORTANCE 60
RELEVANCE 80